Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Effects of Chocolate on Motor Symptoms of Parkinson's Disease (ChocoPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00906763
Recruitment Status : Unknown
Verified May 2010 by Technische Universität Dresden.
Recruitment status was:  Recruiting
First Posted : May 21, 2009
Last Update Posted : May 26, 2010
Information provided by:
Technische Universität Dresden

Brief Summary:

Chocolate consumption has long been associated with enjoyment and pleasure. Popular claims confer on chocolate the properties of being a stimulant, relaxant, euphoriant and antidepressant. These possible pharmacological actions might be related to various biogenic amines, such as serotonin, dopamine, tyramine, histamine, phenylethylamine and cannabinoid-like substances. Most amines are metabolized by monoamineoxidase-A (MAO-A) and are therefore unable to pass the blood-brain-barrier. In contrast, phenylethylamine is a direct dopamine releasing ingredient and as a substrate of MAO-B and due to its lipophilic structure even capable to pass the blood-brain-barrier. Within this line, own clinical observations suggested an increased chocolate consumption in patients with Parkinson's disease (PD) compared to healthy subjects and to their pre-disease state.

In a previous study, we assessed the consumption of chocolate and non-chocolate sweets in PD patients and their partners (as household controls) using a self-questionnaire. Consumption of chocolate was significantly higher in PD patients compared to controls, while consumption of non-chocolate sweets was similar in both groups. Our study suggests that chocolate consumption is increased in PD independent of concomitant depressive symptoms measured by BDI-1. Although reasons for increased chocolate consumption in PD remain elusive, it may hypothetically be a consequence of the high content of various biogenic amines as a content of cocoa influencing dopamine metabolism.

Therefore, in the present study we aim to study the effects of dark chocolate with high cocoa content (85%) compared to chocolate without any cocoa (white chocolate) on motor symptoms in PD patients as measured with UPDRS part III (motor score). The principle design of the intervention is similar to the standard pharmacological challenge test for studying effects on motor symptoms in PD (e.g. levodopa challenge test).

Condition or disease Intervention/treatment Phase
Parkinson's Disease Dietary Supplement: Chocolate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Effects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional Trial
Study Start Date : May 2009
Estimated Primary Completion Date : August 2010
Estimated Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Dark Chocolate (85% cocoa)
Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
Dietary Supplement: Chocolate
A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).

Active Comparator: White chocolate (0% cocoa)
Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
Dietary Supplement: Chocolate
A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).

Primary Outcome Measures :
  1. UPDRS part III [ Time Frame: 1 h after intake of study intervention ]

Secondary Outcome Measures :
  1. Biogenic amines in blood [ Time Frame: 1 to 3 h after study intervention ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age of 18 Years or older
  • Idiopathic Parkinson's disease, according to UKBB criteria
  • Hoehn & Yahr Score II-III
  • 16 Points or more in UPDRS part III scale
  • Sufficient ability to follow the study procedure for at least 3 hours
  • Ability to give informed consent
  • Stable antiparkinsonian medication for at least 4 weeks prior to study inclusion

Exclusion Criteria:

  • Psychiatric conditions, severe enough to interfere with study procedures
  • motor or affective fluctuations or dyskinesias
  • treatment with COMT and/or MAO inhibitors
  • Diabetes mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00906763

Layout table for location contacts
Contact: Martin Wolz, MD ++49-351-458 ext 3106
Contact: Alexander Storch, MD ++49-351-458 ext 2532

Layout table for location information
Dresden University of Technology, Medical Faculty Recruiting
Dresden, Germany, 01307
Contact: Simone Schmidt    ++49-351-458 ext 2524   
Principal Investigator: Martin Wolz, MD         
Sub-Investigator: Alexander Storch, MD         
Sub-Investigator: Christine Schneider, MD         
Sub-Investigator: Lisa Klingelhöfer, MD         
Sub-Investigator: Susann Junghanns, MD         
Sponsors and Collaborators
Technische Universität Dresden
Layout table for investigator information
Principal Investigator: Martin Wolz, MD Technische Universität Dresden

Layout table for additonal information
Responsible Party: Martin Wolz, MD, Dresden University of Technology Identifier: NCT00906763    
Other Study ID Numbers: EK284112008
First Posted: May 21, 2009    Key Record Dates
Last Update Posted: May 26, 2010
Last Verified: May 2010
Keywords provided by Technische Universität Dresden:
Parkinson's disease
Neurodegenerative Disorders
Biogenic amines
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases